Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
Returns on capital
Cabaletta Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.8%
avg -19.2%
ROIC
-123.8%
avg -31.0%
ROA
-101.7%
avg -2816.6%
Analysis
ROA is currently the strongest return metric at -101.7% versus its period average of -2816.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Steven A. Nichtberger | Co-Founder, Chairman, Chief Executive Officer & President | USD 1.13M | 65 | — | — |
David J. Chang FACR | Chief Medical Officer | USD 807.14K | 63 | — | — |
Gwendolyn K. Binder | President of Science & Technology | USD 773.96K | 51 | — | — |
Anup Marda | Chief Financial Officer | USD 548.2K | 48 | 225.00K | 0.14% |
Samik Basu | Chief Scientific Officer | — | — | — | — |
Aimee Payne | Co-Founder & Co-Chair of Scientific Advisory Board | — | — | — | — |
Michael C. Milone | Co-Founder & Co-Chair of Scientific Advisory Board | — | — | — | — |
Qing Sarah Yuan | Chief Technology Officer | — | 55 | — | — |
Michael Gerard | General Counsel & Secretary | — | 46 | 175.00K | 0.11% |
Heather Harte-Hall | Chief Compliance Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$296,188.53
Sells
0
$0.00
Net Transaction Value
+$296,188.53
Net buying
Most Active
Chang David J.
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jan 21, 26Jan 21, 2026 | Chang David J. Direct | Buy | $19.9K$19,888.00 |
| Jan 21, 26Jan 21, 2026 | Binder Gwendolyn Direct | Buy | $24.8K$24,763.10 |
| Jan 21, 26Jan 21, 2026 | Tomasello Shawn Indirect | Buy | $50.3K$50,322.24 |
| Jan 21, 26Jan 21, 2026 | Gavel Steve Direct | Buy | $50.2K$50,215.05 |
| Jan 21, 26Jan 21, 2026 | Bollard Catherine Direct | Buy | $10K$9,982.17 |
| Jan 21, 26Jan 21, 2026 | Nichtberger Steven Direct | Buy | $100.8K$100,777.50 |
| Jan 21, 26Jan 21, 2026 | Simon Mark Direct | Buy | $25.3K$25,261.11 |
| Jan 21, 26Jan 21, 2026 | Gerard Michael Direct | Buy | $15K$14,979.36 |
Summary
Insiders reported 8 buys worth $296,188.53 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $296,188.53. Chang David J. was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Cabaletta Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CABA's management, answered from reported figures.
Who manages CABA?
Cabaletta Bio, Inc. (CABA) lists 10 active executives. The top listed executive is Samik Basu, Chief Scientific Officer.
Are CABA insiders buying or selling?
Recent insider activity shows net selling of $19.54M.
Continue the stock analysis
Jump to another research area for this company.